Format

Send to

Choose Destination
Int J Clin Pharmacol Ther. 2003 Dec;41(12):620-1.

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.

Author information

1
University of Essen, West German Cancer Center, Essen, Germany.
PMID:
14692720
DOI:
10.5414/cpp41620
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center